Psoriasis in a Patient on Peritoneal Dialysis
A Two-sided Mirror

Laurynas Rimsevicius,1,2 Diana Sukackiene,1,2 Giedre Tamulyte,1 Greta Kirkilaite,1 Marius Miglinas1,2

Psoriasis vulgaris is not frequently seen in patients with renal replacement therapy, especially in patients on peritoneal dialysis. Dialysis also has been reported to improve psoriatic skin lesions with a much higher response rate for peritoneal dialysis than haemodialysis. Conversely, we present a case of a man who developed psoriasis after 16 months of peritoneal dialysis. Discontinuation of icodextrin as a possible factor provoking systemic inflammation had no impact on the course of the disease. In this report, we review the existing studies and counsel caution against optimistic expectations of benefits from dialysis in patients with psoriasis.

INTRODUCTION
Psoriasis vulgaris is not frequently seen in patients with renal replacement therapy. A few small-sample studies decades ago reported improvement of psoriatic skin lesions in patients on peritoneal dialysis (PD) or hemodialysis.1-6 Conversely, we present a clinical case with newly developed psoriasis during PD. To our knowledge, there has been only 1 similar case of new-onset psoriasis during PD published in 2014 by Geerse and colleagues,7 and a few cases of psoriasis development during hemodialysis, mostly coming from the 1980s.8-11

CASE REPORT
A 52-year-old man was on predialysis program since 2008 due to malignant hypertension and progressive chronic kidney disease. A Tenckhoff catheter was inserted in January 2014 and automated PD was initiated. The initial prescription consisted of 10-L overnight cycler with 5 exchanges over 9 hours. Later, long icodextrin dwell was added due to edematous state. The patient was twice temporary switched to hemodialysis due to surgical treatment of inguinal and recurrent umbilical hernias. After the surgeries, he carried on nocturnal intermittent PD with irregular use of icodextrin and high-percentage glucose solution during the daytime. In May 2015, the patient started to complain of skin dryness and newly originated itchy, squamous plaques on his hairy part of the scalp skin (Figure 1), on his back, and in external ear canal. The exit site of PD catheter was involved by Koebner phenomenon due to persistent traumatization (Figure 2).

Figure 1. Newly originated itchy squamous plaques on the hairy part of the scalp skin.
The patient had no past history of psoriasis or newly prescribed medication. We discontinued icodextrin as a potential trigger for a period of 2 months; however, there was no improvement. Slight improvement in skin lesions was noted after administering emollients and topical corticosteroids. After this improvement, the patient had his first 3 episodes of PD-associated peritonitis.

DISCUSSION

It is known that dialysis can lead to various skin lesions or worsen them. However, psoriasis is quite rare between patients on hemodialysis with a prevalence of 2.7%. In recent literature, we found 5 cases of hemodialysis patients with new-onset psoriasis. Breathnach and colleagues published a report about a patient treated for 4 years with hemodialysis; Levy and Clutterbuck reported recurred psoriasis over the needling sites after 3 hemodialysis sessions in a patient with antineutrophil cytoplasmic antibody vasculitis; Yamamoto and coworkers reported 2 patients with end-stage renal disease; Triga and coworkers published a clinical case of end-stage renal disease due to polycystic kidney disease treated with hemodialysis for 5 years. Manifestation of psoriasis on PD seems to be even less prevalent.

Several authors had previously reported beneficial effects of dialysis, in particular, with much higher response rate for PD than hemodialysis, on clearing of psoriatic lesion. These publications are demonstrated in the Table. Majority of reports presents positive effects on psoriatic skin lesions of relatively short-term (up to 12 months) or intermittent dialysis. In our case, psoriatic skin changes evolved after treatment with PD for 16 months. Furthermore, reported new-onset psoriasis during hemodialysis generally presents after several months or even years of dialysis.

Another possible hypothesis for psoriasis development is related to pathogenesis of this disease. Chronic systemic inflammation is provoked by systemic disorders such as cardiovascular diseases, diabetes mellitus, and chronic kidney disease. Additionally, the interaction between blood and dialytic membranes provokes secretion of interleukins and other factors that induce systemic inflammation. This immunological activity plays an important role in development of psoriasis. Dysregulation of T helper 1/T helper 2 response and cytokines, such as tumor necrosis factor-α levels, is conditioned by both hemodialysis and PD and depends on duration of treatment. In addition, several authors reported increased levels of interleukin-6 and tumor necrosis factor-α in the effluents of patients receiving PD with icodextrin, suggesting enhanced (peritoneal) inflammatory response. Conversely, use of glucose and lactate-buffered solution released lower concentrations of interleukin-6 and tumor necrosis factor-α. In our case, discontinuation of icodextrin had no impact to psoriasis lesions.

Peritoneal catheter exit-site care was of a big importance in our patient, as it was involved by Koebner phenomenon. The lesion improved with topical treatment. Possibly it can promote higher exit-site or tunnel infection and increase the risk for peritonitis. Exit-site lesion is not a typical indication for catheter removal. However, this patient had 3 episodes of peritonitis, and we considered to replace his PD catheter through a new tunnel.

We would expect the patient to recover from his skin lesions soon, as he was waitlisted as a candidate for kidney transplantation and would be on calcineurin inhibitor. Therefore, we counsel caution against optimistic expectations of benefits from dialysis in patients with psoriasis. There is a need to revise epidemiology of psoriasis in patients with end-stage renal disease.
CONFLICTS OF INTEREST

None declared.

REFERENCES


Psoriasis and Peritoneal Dialysis—Rimsevicius et al


Correspondence to:
Laurynas Rimsevicius, MD PhD
Nephrology Center, Vilnius University hospital Santariskiu klinikos
Santariskiu Street 2, Vilnius LT-08661, Lithuania
Tel.: +370 5 2365 282
E-mail: laurynas.rimsevicius@gmail.com

Received April 2016
Accepted September 2016